Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Atea Pharmaceuticals, Inc. is set to present a business update at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, highlighting its focus on oral antiviral therapeutics for serious viral diseases [1]. Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing oral antiviral therapies to meet the unmet medical needs of patients with serious viral infections [3]. - The company utilizes a proprietary nucleos(t)ide prodrug platform to develop novel product candidates targeting single-stranded ribonucleic acid (ssRNA) viruses, which are significant contributors to serious viral diseases [3]. - Atea's lead program focuses on the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, aimed at treating Hepatitis C Virus (HCV) [3].